Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Le Kremlin-Bicetre – page 189

3 418 clinical trials in Le Kremlin-Bicetre, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Le Kremlin-Bicetre at a glance
3 418
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 418 trials in Le Kremlin-Bicetre

Open in trial search

Hepatitis B virus test+1

Not recruiting

Study on the Effects of Selgantolimod and NUC Discontinuation in Patients with Chronic Hepatitis B

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Entecavir
  • Sponsor:ANRS Maladies Infectieuses Emergentes

Dermatomyositis

Not recruiting

Study on Baricitinib for Treating New-Onset Juvenile Dermatomyositis in Children

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Assistance Publique Hopitaux De Paris

Enteritis

Not recruiting

Study on Preventing Recurrent Pouchitis in Ulcerative Colitis Patients Using Fecal Microbiota Transplant and Sodium Chloride

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Nephrotic syndrome

Not recruiting

Study of Rituximab, Prednisolone and Betamethasone in Adult Patients with First Episode of Minimal Change Nephrotic Syndrome to Prevent Disease Relapse

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Prednisolone
  • Sponsor:Assistance Publique Hopitaux De Paris

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Neoplasm

Not recruiting

Study of RLY-4008 for Patients with Cholangiocarcinoma and Other Advanced Solid Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:RLY-4008
  • Sponsor:Elevar Therapeutics Inc.

Acute myeloid leukaemia+1

Not recruiting

Study of Emavusertib for Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Emavusertib
  • Sponsor:Curis Inc.

Study Comparing Ripretinib and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors Previously Treated with Imatinib

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ripretinib
  • Sponsor:Deciphera Pharmaceuticals Inc.

Plasma cell myeloma

Not recruiting

Study of Elranatamab for Patients with Multiple Myeloma Resistant to Proteasome Inhibitors, Immunomodulatory Drugs, and Anti-CD38 Antibodies

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Pfizer Inc.

Study Comparing Avelumab, Cetuximab, and Radiotherapy with Standard Treatments for Patients with Advanced Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Fallopian tube cancer+2

Not recruiting

Study of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nemvaleukin Alfa
  • Sponsor:Mural Oncology Inc.

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Pfizer Inc.

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Le Kremlin-Bicetre

What the registry says about research in the country

01 Bacterial Infections and Mycoses

Research in this area focuses on bacterial infections, especially severe ear, nose and throat diseases such as idiopathic purulent oedematous sinusitis in adults. The trials are aimed at evaluating whether treatment can improve symptoms and overall patient well-being.

  • Testing a treatment approach for persistent sinus infection
  • Assessing improvement in quality of life over time

In Kremlin Bicêtre, this work reflects a practical effort to better manage chronic ENT infection-related complaints.

02 Cardiovascular Diseases

Clinical research here also covers cardiovascular disease in patients hospitalized for septic shock with tachycardia and hypercontractility. The main goal is to evaluate whether controlling heart rate may help improve survival and clinical outcomes.

  • Studying a heart-rate-lowering strategy in septic shock
  • Comparing outcomes against standard care

These trials are designed to clarify whether better cardiovascular support can reduce risk in critically ill patients.

03 Otorhinolaryngologic Diseases

Another key research focus is otorhinolaryngology, with attention on sinusitis and related ENT disorders. The studies are looking at treatment effectiveness and changes in patient-reported symptoms during follow-up.

  • Measuring symptom relief in sinus disease
  • Tracking changes in disease-specific quality of life

This area highlights efforts to improve everyday functioning for patients living with ongoing nasal and sinus problems.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.